文献速递泌尿生殖MRUS

靶向MRI引导的微超声活检检测临床显著性前列腺癌

Detection of clinically significant prostate cancer using targeted MRI-informed microultrasound biopsy.
PubMed 文献 · Eur Radiol · 2025-11-22

单中心回顾性研究纳入169例患者244个mpMRI病灶,行mpMRI引导的微超声靶向活检,临床显著性前列腺癌检出率与既往同机构mpMRI-超声融合活检数据无显著差异(p>0.05);微超声仅见病灶的靶向活检额外检出3例临床显著性前列腺癌。

要点

  • mpMRI病灶在微超声上可见者临床显著性前列腺癌阳性预测值为0.37,未见对应病灶者为0.18(p<0.05)。
  • 靶向PI-RADS 5、4、3病灶的临床显著性前列腺癌阳性预测值分别为0.64、0.31、0.12。
  • 微超声仅见而mpMRI未见病灶的靶向活检额外检出3例临床显著性前列腺癌(73/169,43.2%)。

核心结论

  • 回顾性研究显示微超声引导活检实施成功,临床显著性前列腺癌检出率与既往mpMRI-超声融合活检历史数据相似(p>0.05)。

研究设计与样本

  • 单中心回顾性研究,纳入169例患者244个mpMRI检出病灶,行mpMRI引导的微超声靶向活检,并与同机构已发表的mpMRI-超声融合平台数据比较。

关键影像表现/征象

  • 244个mpMRI病灶中206个(84.4%)在微超声上可见。
  • 微超声额外检出26个mpMRI未见病灶。
  • 244个病灶中PI-RADS 5、4、3分别为44个(18.0%)、167个(68.4%)、33个(13.5%)。

诊断标准与关键数值

  • 靶向活检检出前列腺癌120/169(71.0%),临床显著性前列腺癌70/169(41.4%)。
  • PI-RADS 5、4、3病灶靶向活检检出所有前列腺癌的阳性预测值分别为0.80、0.61、0.39。
  • PI-RADS 5、4、3病灶靶向活检检出临床显著性前列腺癌的阳性预测值分别为0.64、0.31、0.12。
  • 微超声未见对应病灶的mpMRI病灶临床显著性前列腺癌阳性预测值为0.18,可见对应病灶者为0.37(p<0.05)。
  • 微超声仅见病灶的靶向活检使临床显著性前列腺癌检出增至73/169(43.2%)。

临床应用与阅片要点

  • 作者认为微超声引导活检表现与mpMRI-超声融合活检相当,支持两者联合应用以提高临床显著性前列腺癌检出。
  • 阅片时需注意mpMRI病灶在微超声上无对应显示者临床显著性前列腺癌阳性预测值较低(0.18),而可见对应病灶者较高(0.37)。

局限性

  • 原文为单中心回顾性研究。
  • 与历史已发表数据进行比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study compares the rate of detection of clinically significant prostate cancer (csPCa) using multiparametric MRI (mpMRI)-informed microultrasound-guided (microUS) biopsy to historical published data using mpMRI-ultrasound (mpMRI-US) fusion biopsy at the same institution.

MATERIALS AND METHODS: A single-center retrospective study of patients who underwent mpMRI-informed microultrasound-guided (microUS) biopsy was performed. Positive predictive value (PPV) of targeted lesions by PI-RADS and PRI-MUS (Prostate Risk Identification Using Microultrasound) was calculated and compared to published data using an mpMRI-US fusion platform.

RESULTS: 169 subjects and 244 total lesions were identified by mpMRI. 44/244 (18.0%), 167/244 (68.4%), and 33/244 (13.5%) were PI-RADS 5, 4, and 3, respectively. 206/244 (84.4%) lesions seen on mpMRI were identified on microUS. 26 additional lesions were identified by microUS only. PCa was identified in 120/169 (71.0%) patients, and csPCa was identified in 70/169 (41.4%) by targeted microUS-guided biopsy of MRI lesions. Targeted biopsy of lesions seen only on microUS added three cases of csPCa (73/169, 43.2%). PPV of targeted PI-RADS 5, 4, and 3 lesions for all PCa and csPCa was 0.80, 0.61, and 0.39, and 0.64, 0.31, and 0.12, respectively. Findings were not significantly different compared to historical data using mpMRI-US fusion biopsy (p > 0.05). PPV for csPCa was 0.18 for mpMRI lesions when no correlate was identified by microUS, compared to 0.37 for lesions when a correlate was seen (p < 0.05).

CONCLUSIONS: This retrospective study demonstrates successful implementation of microUS-guided biopsy, with similar rates of identification of csPCa compared to historical data using mpMRI-US fusion.

KEY POINTS: Question There is limited real-world comparison of the rate of detection of clinically significant prostate cancer using mpMRI-informed microUS-guided biopsy compared to historical mpMRI-ultrasound fusion biopsy. Findings Identification of clinically significant prostate cancer by microUS-guided biopsy was similar to mpMRI-US fusion biopsy, suggesting microUS-guided biopsy performs as well as mpMRI-US fusion biopsy. Clinical relevance Our study shows the complementary role of mpMRI and microUS for the detection of clinically significant prostate cancer, supporting the combined approach of these techniques.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Forrest AB, Kruse DE, Calio B, et al. Detection of clinically significant prostate cancer using targeted MRI-informed microultrasound biopsy. Eur Radiol. 2025. PMID: 41273426. doi:10.1007/s00330-025-12136-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。